← All trials
NCT02960594
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2014
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 54
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- Inovio PharmaceuticalsLead sponsor
- University of PennsylvaniaCollaborator
- Thomas Jefferson UniversityCollaborator
- University of PittsburghCollaborator
- Wayne State UniversityCollaborator
- Mayo ClinicCollaborator
- University of PennsylvaniaOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- Thomas Jefferson UniversityOverall official - principal investigator
- Wayne State UniversityOverall official - principal investigator
- University of North Carolina at Chapel HillCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.